Immune microenvironment changes induced by neoadjuvant chemotherapy in triple-negative breast cancers: the MIMOSA-1 study
Abstract Background The immune microenvironment (IME) of triple-negative breast cancers (TNBCs) and its modulation by neoadjuvant chemotherapy (NACT) remain to be fully characterized. Our current study aims to evaluate NACT-induced IME changes and assess the prognostic value of specific immune bioma...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-05-01
|
Series: | Breast Cancer Research |
Subjects: | |
Online Access: | https://doi.org/10.1186/s13058-021-01437-4 |
id |
doaj-1e4648556cd94fd8825881faa3eb2701 |
---|---|
record_format |
Article |
spelling |
doaj-1e4648556cd94fd8825881faa3eb27012021-05-30T11:32:58ZengBMCBreast Cancer Research1465-542X2021-05-0123111110.1186/s13058-021-01437-4Immune microenvironment changes induced by neoadjuvant chemotherapy in triple-negative breast cancers: the MIMOSA-1 studyVictor Sarradin0Amélie Lusque1Thomas Filleron2Florence Dalenc3Camille Franchet4Department of Medical Oncology, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse, IUCT-OncopoleDepartment of Biostatistics, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse, IUCT-OncopoleDepartment of Biostatistics, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse, IUCT-OncopoleDepartment of Medical Oncology, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse, IUCT-OncopoleDepartment of Pathology, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse, IUCT-OncopoleAbstract Background The immune microenvironment (IME) of triple-negative breast cancers (TNBCs) and its modulation by neoadjuvant chemotherapy (NACT) remain to be fully characterized. Our current study aims to evaluate NACT-induced IME changes and assess the prognostic value of specific immune biomarkers. Methods Tumor-infiltrating lymphocytes (TILs) were identified from hematoxylin-eosin-stained sections of paired pre- and post-NACT tumor samples from a TNBC cohort (n = 66) and expression of PD-L1, TIM-3, and LAG-3 evaluated by immunohistochemistry. Results Overall TIL counts and PD-L1 expression did not differ pre- and post-NACT, but there was a response-specific statistically significant difference. TIL counts decreased in 65.5% of patients who achieved a pathological complete response (pCR) and increased in 56.8% of no-pCR patients (p = 0.0092). PD-L1 expression was significantly more frequently lost after NACT in pCR than in no-pCR patients (41.4% vs 16.2%, p = 0.0020). TIM-3 positivity (≥ 1%) was significantly more frequent after NACT (p < 0.0001) with increases in expression levels occurring more frequently in no-pCR than in pCR patients (51.4% vs 31%). LAG-3 expression significantly decreased after NACT, but there was no difference between response groups. Before NACT, a high TIL count (> 10%) was significantly associated with better overall survival (OS), p = 0.0112. After NACT, PD-L1 positivity and strong TIM-3 positivity (≥ 5%) were both associated with significantly worse OS (p = 0.0055 and p = 0.0274, respectively). Patients positive for both PD-L1 and TIM-3 had the worst prognosis (p = 0.0020), even when only considering patients who failed to achieve a pCR, p = 0.0479. Conclusions NACT induces significant IME changes in TNBCs. PD-L1 and TIM-3 expression post-NACT may yield important prognostic information for TNBC patients.https://doi.org/10.1186/s13058-021-01437-4Triple-negative breast cancerNeoadjuvant chemotherapyImmune microenvironmentTumor-infiltrating lymphocytesTILsPD-L1 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Victor Sarradin Amélie Lusque Thomas Filleron Florence Dalenc Camille Franchet |
spellingShingle |
Victor Sarradin Amélie Lusque Thomas Filleron Florence Dalenc Camille Franchet Immune microenvironment changes induced by neoadjuvant chemotherapy in triple-negative breast cancers: the MIMOSA-1 study Breast Cancer Research Triple-negative breast cancer Neoadjuvant chemotherapy Immune microenvironment Tumor-infiltrating lymphocytes TILs PD-L1 |
author_facet |
Victor Sarradin Amélie Lusque Thomas Filleron Florence Dalenc Camille Franchet |
author_sort |
Victor Sarradin |
title |
Immune microenvironment changes induced by neoadjuvant chemotherapy in triple-negative breast cancers: the MIMOSA-1 study |
title_short |
Immune microenvironment changes induced by neoadjuvant chemotherapy in triple-negative breast cancers: the MIMOSA-1 study |
title_full |
Immune microenvironment changes induced by neoadjuvant chemotherapy in triple-negative breast cancers: the MIMOSA-1 study |
title_fullStr |
Immune microenvironment changes induced by neoadjuvant chemotherapy in triple-negative breast cancers: the MIMOSA-1 study |
title_full_unstemmed |
Immune microenvironment changes induced by neoadjuvant chemotherapy in triple-negative breast cancers: the MIMOSA-1 study |
title_sort |
immune microenvironment changes induced by neoadjuvant chemotherapy in triple-negative breast cancers: the mimosa-1 study |
publisher |
BMC |
series |
Breast Cancer Research |
issn |
1465-542X |
publishDate |
2021-05-01 |
description |
Abstract Background The immune microenvironment (IME) of triple-negative breast cancers (TNBCs) and its modulation by neoadjuvant chemotherapy (NACT) remain to be fully characterized. Our current study aims to evaluate NACT-induced IME changes and assess the prognostic value of specific immune biomarkers. Methods Tumor-infiltrating lymphocytes (TILs) were identified from hematoxylin-eosin-stained sections of paired pre- and post-NACT tumor samples from a TNBC cohort (n = 66) and expression of PD-L1, TIM-3, and LAG-3 evaluated by immunohistochemistry. Results Overall TIL counts and PD-L1 expression did not differ pre- and post-NACT, but there was a response-specific statistically significant difference. TIL counts decreased in 65.5% of patients who achieved a pathological complete response (pCR) and increased in 56.8% of no-pCR patients (p = 0.0092). PD-L1 expression was significantly more frequently lost after NACT in pCR than in no-pCR patients (41.4% vs 16.2%, p = 0.0020). TIM-3 positivity (≥ 1%) was significantly more frequent after NACT (p < 0.0001) with increases in expression levels occurring more frequently in no-pCR than in pCR patients (51.4% vs 31%). LAG-3 expression significantly decreased after NACT, but there was no difference between response groups. Before NACT, a high TIL count (> 10%) was significantly associated with better overall survival (OS), p = 0.0112. After NACT, PD-L1 positivity and strong TIM-3 positivity (≥ 5%) were both associated with significantly worse OS (p = 0.0055 and p = 0.0274, respectively). Patients positive for both PD-L1 and TIM-3 had the worst prognosis (p = 0.0020), even when only considering patients who failed to achieve a pCR, p = 0.0479. Conclusions NACT induces significant IME changes in TNBCs. PD-L1 and TIM-3 expression post-NACT may yield important prognostic information for TNBC patients. |
topic |
Triple-negative breast cancer Neoadjuvant chemotherapy Immune microenvironment Tumor-infiltrating lymphocytes TILs PD-L1 |
url |
https://doi.org/10.1186/s13058-021-01437-4 |
work_keys_str_mv |
AT victorsarradin immunemicroenvironmentchangesinducedbyneoadjuvantchemotherapyintriplenegativebreastcancersthemimosa1study AT amelielusque immunemicroenvironmentchangesinducedbyneoadjuvantchemotherapyintriplenegativebreastcancersthemimosa1study AT thomasfilleron immunemicroenvironmentchangesinducedbyneoadjuvantchemotherapyintriplenegativebreastcancersthemimosa1study AT florencedalenc immunemicroenvironmentchangesinducedbyneoadjuvantchemotherapyintriplenegativebreastcancersthemimosa1study AT camillefranchet immunemicroenvironmentchangesinducedbyneoadjuvantchemotherapyintriplenegativebreastcancersthemimosa1study |
_version_ |
1721420227607003136 |